The Latest Cardiac and Vascular News
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, has announced the first patient enrollment in the Perceval® Valve Clinical study for Chinese Registration (“PERFECT”) Trial. The study is a pre-market, prospective, single-arm trial. The PERFECT trial is being conducted to demonstrate the safety and effectiveness of […]
IRVINE, Calif., March 21, 2018 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that enrollment is complete in the computed tomography (CT) imaging sub-study within the PARTNER 3 trial of the SAPIEN 3 valve. This randomized sub-study is examining […]
ALAMEDA, Calif., March 21, 2018 /PRNewswire/ — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singulex cTnI assay and Single Molecule Counting technology can independently predict moderate and severe coronary disease (CAD), suggesting its clinical utility for accurate, safe and cost-effective evaluation of patients in an outpatient setting, […]
DURHAM, N.C., March 20, 2018 /PRNewswire/ — Micell® Technologies, Inc., a privately-held, development-stage biomedical company, today provided an update on its recently expanded intellectual property portfolio. With the granting of 24 patents in 2017, including eight that issued in the fourth quarter, Micell’s extensive intellectual property portfolio comprises 186 patents (166 issued […]
ABBOTT PARK, Ill., March 19, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the Ministry of Health Labour and Welfare (MHLW) in Japan granted national reimbursement for the company’s MitraClip therapy to treat people with mitral regurgitation, a serious, progressive heart disease in which the mitral valve does not close properly, […]
MINNEAPOLIS, March 14, 2018 /PRNewswire/ — Mardil Medical Inc., today announced the first human implants of its VenTouch® Triad device. Designed as a combination therapy to simultaneously treat the dilated ventricle and the resulting distorted valve in patients suffering from Type IIIb Functional Mitral Valve Regurgitation (FMR), VenTouch is a less-invasive treatment for a […]
SAN RAMON, Calif., and HOUMA, La., March 12, 2018 /PRNewswire/ — BioVentrix, Inc., a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced successful treatment of the first patient at the Cardiovascular Institute of the South in the ALIVE pivotal clinical trial. The trial is […]
ORLANDO, Fla., March 11, 2018 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a new analysis showing that INVOKANA® (canagliflozin) significantly reduced the risk of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) at high CV risk. This exploratory […]
BURLINGTON, Mass.–(BUSINESS WIRE)– InfraReDx, Inc., a pioneer in intravascular imaging for mapping coronary artery disease, today presented a poster at the American College of Cardiology (ACC) 67th Annual Scientific Session supporting the value of combination intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) imaging technology to identify lipid core plaque (LCP), an underlying cause of serious […]
AMSTERDAM and ORLANDO, Florida, March 10, 2018 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced health economic results from the DEFINE FLAIR clinical trial comparing cost-effectiveness between instant wave-free ratio (iFR) and fractional flow reserve (FFR) in the guidance of treatment of ischemic heart […]
